Neuravi, a company dedicated to improving clinical outcomes for stroke patients, was honored to meet with Ireland’s Prime Minister, Enda Kenny, last week at an event hosted by Enterprise Ireland in Amsterdam recognizing business agreements between Irish and Benelux companies.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160112006335/en/
Julie Sinnamon, Enterprise Ireland; Paul Geudens, Neuravi; Anne Portwich, Life Science Partners; Enda Kenny, Prime Minister of Ireland; Alexander de Vries, Angiocare BV; and Prof. Dr. Charles Majoie, Academisch Medisch Centrum Amsterdam (L-R) (Photo: Business Wire)
Neuravi is building a strong market position in the Netherlands with notable deals and partnerships. In June 2015, Amsterdam-based healthcare investment firm Life Science Partners (LSP) led the €19M ($21M) Series B financing of Neuravi. In August 2015, Angiocare BV of Eemnes, the Netherlands, signed a distribution agreement with Neuravi to become the exclusive distributor of its EmboTrap® Revascularization Device in the Netherlands.
Paul Geudens, vice president of EMEA sales and marketing, represented Neuravi at the event. Joining him were Anne Portwich, partner at LSP and a Neuravi board member; Alexander de Vries, partner at Angiocare BV; and Prof. Dr. Charles Majoie of the Academisch Medisch Centrum Amsterdam.
Professor Majoie was one of the lead investigators in the MR CLEAN trial, a study funded by the Dutch Heart Foundation and others, which produced the first definitive clinical evidence of the benefit of mechanical thrombectomy in treating large vessel acute ischemic stroke. Neuravi and Prof. Majoie’s team are collaborating on developing a better understanding of the clots that cause ischemic stroke.
“Ireland now has over 350 medtech firms employing 25,000 people with exports of around €8.5 billion a year. Neuravi has emerged as a leader in this sector and its commercial progress in Europe has been impressive. I am delighted to introduce Neuravi and its partners to the Taoiseach (Prime Minister) to recognise these important contributions to business and healthcare in the Benelux region. These collaborations reflect Neuravi’s depth of commitment in addressing the needs of stroke-affected patients,” stated Julie Sinnamon, CEO, Enterprise Ireland.
Paul Geudens commented, “Neuravi recognizes the value in partnering with outstanding organizations in order to build a strong presence in the Netherlands. We are proud to team with Dutch leaders like LSP and Angiocare. We also look forward to our collaborative work with Prof. Majoie on better understanding the characteristics of clot that cause stroke and the implications for treatment.”
“While the field of stroke therapy has advanced tremendously over this past year, significant opportunity remains to further improve patient outcomes,” noted Professor Majoie. “Studying the culprit clot is one of the areas likely to impact treatment strategies, and so our work with Neuravi will be valuable in this endeavor.”
Enterprise Ireland is the government organization responsible for the development and growth of Irish enterprises in world markets. It works in partnership with Irish enterprises to help them start, grow, innovate and win export sales in global markets.
About Neuravi
Based in Galway, Ireland, Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s initial stroke therapy platform, the EmboTrap Revascularization Device, is CE marked, and commercially available in Europe. Neuravi’s ARISE II clinical trial has started enrolling patients at select centers in the United States and Europe. The trial will gather data to support the use of the EmboTrap and to seek FDA approval. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke. Neuravi is led by a team experienced in endovascular device development and global commercialization. More information can be found at www.neuravi.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160112006335/en/
